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Introduction of antiretroviral combination therapy has profoundly altered both the course and 
prognosis of the disease in HIV-infected persons. Recent data, however, have raised concerns 
that antiretroviral combination therapy is associated with premature manifestation of coronary 
artery disease.[1] In particular, protease inhibitors have been linked to metabolic changes such as 
insulin resistance, abnormalities in lipid metabolism and lipodystrophy and increased coronary 
artery calcification. While previous studies have reached conflicting conclusions about the 
incidence of myocardial infarction, the most substantial database recently provided by Friis-
Møller and co-workers demonstrated an increased incidence in HIV-infected persons on protease 
inhibitors or non-nucleosid reverse transcriptase inhibitor-containing therapy.[2] 
One of the postulated mechanisms of proatherogenic effects of protease inhibitors is the 
promotion of atherosclerotic lesion formation by an increase in CD-36-dependent cholesteryl 
ester accumulation in macrophages. Additionally, hypercholesterolemia promotes a CD-36-
dependent and endothelial nitric oxide synthase mediated endothelial dysfunction. Endothelial 
dysfunction is associated with future risk of adverse cardiovascular events.[3] Impaired 
endothelial function was previously shown in HIV-infected persons on protease inhibitor 
therapy.[4] The effect of statins (HMG-CoA reductase inhibitors) in antiretroviral combination 
therapy associated dyslipidemia remains still to be determined. As most statins are metabolized 
by the cytochrome P450 3A4 isoform and thus interfere with the metabolism of many 
antiretroviral drugs, resulting in increased toxicity, cytochrome P450-independent statins such as 
pravastatin may be advantageous. 
Hence, the present study aimed to evaluate the effects of pravastatin on endothelial function 
and plasma lipid profile in persons on protease inhibitor-containing antiretroviral combination 
therapy. 
 
METHODS 
This was a randomized, cross-over, double-blind and placebo-controlled interventional trial 
investigating pravastatin 40mg daily and matching placebo for 8 weeks each. Laboratory, 
clinical and endothelial function parameters were assessed at baseline and after each treatment 
period. An additional ultrasound measurement was performed at 4 weeks. Inclusion criteria were 
HIV-infection, protease inhibitor-containing antiretroviral combination therapy for at least 4 
months that was unchanged for 2 months. Exclusion criteria were cholesterol <5mmol/L, statins 
or ACE inhibitors, diabetes mellitus and acute coronary syndromes within the previous 4 weeks. 
Concomitant medication remained unchanged throughout the study course. Each patient gave 
written informed consent and the study was approved by the local ethics committee of the 
University Hospital of Zurich. 
Brachial artery endothelium-dependent flow-mediated dilation (FMD), induced by inflation 
of a wrist cuff to suprasystolic pressure for 5 minutes, and endothelium-independent vasodilation 
(0.4mg glycerol trinitrate sublingually) were assessed by a high-resolution ultrasound vessel wall 
tracking device with a 10-MHz linear array transducer (ESAOTE AU-5, WTS-2, Pie Medical, 
Maastricht, The Netherlands). Vessel diameter was recorded every 15 seconds for 5 minutes.    
All data is presented as medians and interquartile range as 25th to 75th percentile. For 
changes of FMD and lipid parameters comparing pravastatin to placebo Wilcoxon signed rank 
test was used. For comparison of baseline characteristics Mann-Whitney test was used. 
Statistical significance was accepted at p<0.05. Results of linear univariable and multivariable 
regression analysis are expressed as regression co-efficients±SEM.  
 
RESULTS 
29 participants (median age 43 years, 79% male) were included for final analysis. Baseline 
patients' characteristics between the two treatment arms did not differ. HIV parameters were: 
previous clinical AIDS, 10 of 29 (34%) patients; median CD4 lymphocyte nadir and baseline 
count, 93 x 103 (range, 45-245) and 484 (328-633) cells/mL, respectively; median duration of 
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antiretroviral therapy, 4.8 (2.3-5.9) years; median baseline HIV-1 RNA below 50 copies/mL. 
During the study, no progression of HIV infection was observed. 
8 weeks of treatment with pravastatin significantly improved FMD v both baseline (p=0.003) 
and placebo (p=0.03) (figure 1 and 2, table 1). At 4 weeks, FMD was not different between 
pravastatin and placebo (p=0.12). A mild carry over effect was perceivable: FMD after 4 weeks 
of placebo in the group first receiving pravastatin was increased v baseline (2.6% v 1.6%, 
p=0.01), resembling the preceding 8 week pravastatin measure point (2.6%, p=0.48). In contrast, 
in patients who first received placebo, FMD was comparable to baseline (2.3% v 2.8%, p=0.26) 
after 4 weeks of placebo. GTN induced vasodilation was not influenced by either treatment. 
Values for plasma creatinine, creatinine kinase, AST, ALT and glucose were within normal 
limits at baseline and did not change during the study. Laboratory and clinical parameters are 
summarized in table 1. 
 
Table 1: Comparison of parameters at baseline and after 8 weeks of placebo and pravastatin treatment, 
respectively* 
 Baseline 
 
N=29 
Placebo 
8 weeks 
N=29 
Pravastatin 
8 weeks 
N=29 
p 
pravastatin/ 
baseline 
p 
pravastatin/ 
placebo 
HIV surrogate markers      
CD4 cell count (103 cells/mL) 484 (328-633) 472 (320-646) 464 (354-650) 0.60 0.42 
HIV-1 RNA (copies/mL) 8 (0-37) 0 (0-22) 0 (0-18) 0.57 0.33 
Clinical parameters      
Body mass index (kg/m2) 22.9 (21.4-25.1) 23.1 (21.3-25.1) 22.6(21.2-25.4) 0.53 0.93 
Systolic blood pressure (mmHg) 120 (114-128) 118 (114-129) 119 (113-127) 0.33 0.99 
Diastolic blood pressure (mmHg) 77 (71-83) 78 (73-83) 76 (71-84) 0.41 0.95 
Heart rate (bpm) 76 (71-81)  75 (70-82) 75 (71-80) 0.85 0.47 
Laboratory parameters      
Total cholesterol (mmol/L) 6.4 (6.0-7.4) 6.4 (5.3-7.2) 5.5 (4.8-6.3) <0.0001 0.001 
HDL cholesterol (mmol/L) 1.2 (1.1-1.6) 1.2 (1.0-1.6) 1.3 (1.1-1.4) 0.90 0.38 
LDL cholesterol (mmol/L) 3.7 (2.8-4.2) 3.9 (2.7-4.4) 3.0 (2.4-3.7) 0.001 0.01 
Triglycerides (mmol/L) 3.0 (2.1-4.0) 2.7 (2.1-3.8) 2.3 (1.6-2.9) 0.05 0.04 
Oxidized LDL (IU) 53 (45-66) 55 (43-70) 47 (38-57) 0.0003 0.007 
hs CRP (mg/L) 2.2 (0.7-4.5) 2.1 (0.8-5.1) 2.1 (1.0-4.8) 0.50 0.29 
Endothelial Function      
FMD (%) 2.0 (1.5-2.6) 2.5 (1.8-3.2) 3.2 (1.9-4.1) 0.003 0.03 
GTN induced vasodilatation (%) 11.3 (10.0-14.4) 11.3 (9.6-16.3) 10.8 (7.0-15.7) 0.16 0.85 
Vessel diameter (mm) 4.4 (4.1-4.8) 4.3 (3.8-4.6) 4.3 (3.9-4.8) 0.26 0.65 
*Numbers represent medians (interquartile range) unless otherwise stated 
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Change of LDL cholesterol was found to be inversely related to percentage change of FMD 
(r=0.36, p=0.014). This relationship remained significant in a multivariable model additionally 
including treatment sequence and heart rate as independent variables (r=0.53, p=0.003). 
 
DISCUSSION 
This randomized, double-blind investigation demonstrates that statin therapy not only lowers 
total, LDL- as well as oxidized LDL cholesterol, but significantly improves endothelial function 
in HIV-infected persons on protease inhibitors-containing antiretroviral combination therapy. 
HIV infection has become a chronic disease, requiring long-term management strategies and 
greater attention to disease prevention issues. As such statins are expected to become a 
cornerstone of coronary artery disease prevention since emerging evidence suggests that HIV-
infected persons on antiretroviral combination therapy, particularly on protease inhibitor-
containing regimens, are at increased risk for cardiovascular morbidity and mortality by 
mechanism that are not fully understood yet.[1][2] Our study provides evidence that statins 
improve a clinically relevant cardiovascular surrogate endpoint and further corroborate and 
extend findings of a recent study by Stein showing a trend towards improvement of FMD in HIV 
patients. While significant beneficial effects of statins on vascular endothelial function have 
previously been demonstrated in a range of patient populations with hypercholesterolemia, the 
present study extends these results to HIV-positive individuals. The decrease in total cholesterol 
and LDL in the present study was considerably less than reported from large lipid-lowering 
studies using identical doses of pravastatin in hypercholesterolemic subjects. The relatively 
modest effects on plasma lipids in the present and previous studies in HIV patients may in part 
be explained by pharmacokinetic interactions. Indeed, in combination with protease inhibitors 
plasma concentration of simvastatin increased 30-fold, while pravastatin levels were found to 
decline by 50%.[5]   
In conclusion, notwithstanding the results of the present study demonstrate that statin 
therapy beneficially impacts on a clinically relevant surrogate marker of cardiovascular disease, 
the definitive answer as to the net effect of statins on cardiovascular events in HIV patients can 
only be provided by large scale prospective randomized clinical trials. 
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LEGENDS TO FIGURES 
 
Figure 1:  
8 weeks of treatment with pravastatin resulted in a significant improvement of FMD (3.2% (1.9-
4.1)) v both baseline (2.0% (1.5-2.6), p=0.003) and placebo (2.5% (1.8-3.2), p=0.03).  
 
Figure 2:  
Individual changes in FMD from baseline resulted in a significant improvement after 8 weeks of 
pravastatin (1.2%, p=0.003) but not after 4 weeks (0.3%, p=0.2). Placebo did not alter FMD at 8 
weeks (0.5%, p=0.48) while FMD after 4 weeks of placebo was slightly increased v baseline 
(0.6%, p=0.01), which is largely attributable to a carry-over effect in the cross-over design. At 4 
weeks, change of FMD did not vary between pravastatin and placebo (p=0.12).  
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